This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2022 Remove Clinical Pharmacology Remove Process Chemistry Related Topics
Metabolic Stability FDA Approval Clinical Development Virus Therapies Trials Treatment Disease Drugs FDA More Related Topics >
article thumbnail

Metabolism of macrocyclic drugs

Metabolite Tales Blog

JULY 5, 2023

Synthetic macrocycles in oncology Pactritinib is a multi-kinase JAK2/FLT3 inhibitor used for the treatment of primary and secondary myelofibrosis, approved by the FDA in 2022. Journal of Medicinal Chemistry, 66 (8), 5377-5396. Journal of Medicinal Chemistry 62 (21), 9418-9437. Ayushi Jain and Khalid Mumtaz, 2022.

Metabolic Stability 52
Metabolic Stability Drugs FDA Approval Treatment 52
article thumbnail

Metabolism of de novo designed macrocyclic drugs

Metabolite Tales Blog

JULY 5, 2023

Synthetic macrocycles in oncology Pactritinib is a multi-kinase inhibitor used for the treatment of primary and secondary myelofibrosis and was approved by the FDA in 2022. Journal of Medicinal Chemistry, 66 (8), 5377-5396. Journal of Medicinal Chemistry 62 (21), 9418-9437. Ayushi Jain and Khalid Mumtaz, 2022. Chen et al.,

Metabolic Stability 52
Metabolic Stability Drugs FDA Approval Treatment 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024